IGC Pharma, Inc. (IGC): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Not updated since 2025-03-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2018-03-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$6.83M
Year ended 2025-03-31
-$7.52M
Trailing 12 months to 2025-09-30
2011-03-31: -$15.10M2012-03-31: -$6.52M2013-03-31: -$1.81M2014-03-31: -$1.82M2015-03-31: -$3.56M2016-03-31: -$2.18M2017-03-31: -$1.66M2018-03-31: -$1.77M2019-03-31: -$4.58M2020-03-31: -$6.72M2021-03-31: -$8.25M2022-03-31: -$14.78M2023-03-31: -$10.91M2024-03-31: -$9.16M2025-03-31: -$6.83M-$6.83M
2011-03-31 EBITDA (USD) 2025-03-31
Period endedEBITDAChange YoYSource filing
2025-03-31-$6.83Mn/m2025-06-27, From 2024-04-01
2024-03-31-$9.16Mn/m2025-06-27, From 2023-04-01
2023-03-31-$10.91Mn/m2024-06-24, From 2022-04-01
2022-03-31-$14.78Mn/m2023-07-07, From 2021-04-01
2021-03-31-$8.25Mn/m2022-06-23, From 2020-04-01
2020-03-31-$6.72Mn/m2021-06-14, From 2019-04-01
2019-03-31-$4.58Mn/m2020-07-13, From 2018-04-01
2018-03-31-$1.77Mn/c2019-06-14, From 2017-04-01
2017-03-31-$1.66Mn/m2018-06-21, From 2016-04-01
2016-03-31-$2.18Mn/m2017-07-14, From 2015-04-01
2015-03-31-$3.56Mn/m2016-07-14, From 2014-04-01
2014-03-31-$1.82Mn/m2015-07-14, From 2013-04-01
2013-03-31-$1.81Mn/m2014-07-15, From 2012-04-01
2012-03-31-$6.52Mn/m2014-07-15, From 2011-04-01
2011-03-31-$15.10Mn/a2012-07-16, From 2010-04-01